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One-sentence summary: The signaling proteins and pathways involved in lymphatic endothelial 
cell migration are identified.  
 
Editor’s summary: 
Moving lymphatic endothelial cells about 
Lymphatic vessels return fluid and immune cells from peripheral tissues back to the circulation. 
The growth of new lymphatic vessels and their remodeling are critical for clearing infection and 
for metastasis of many cancer subtypes. Williams et al. compared the results of their functional 
siRNA screens with previously published mRNA datasets to identify genes that regulated 
lymphatic endothelial cell migration, a process critical for lymphatic vessel growth and 
remodeling, and genes that functioned in both lymphatic and blood endothelial cell migration. 
One of the top candidates to emerge from these analyses, the glycan-binding protein Galectin-1, 
not only promoted lymphatic vessel growth, but was also important for maintaining lymphatic 
endothelial cell identity. Further analyses of the authors’ results may reveal lymphatic vessel–
associated proteins that could be targeted to prevent edema, improve infection outcomes, or limit 
metastasis. 
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Abstract 
Lymphatic vessels constitute a specialized vasculature that is involved in development, 
cancer, obesity and immune regulation. The migration of lymphatic endothelial cells 
(LECs) is critical for vessel growth (lymphangiogenesis) and vessel remodelling, 
processes that modify the lymphatic network in response to developmental or 
pathological demands. Using the publicly accessible results of our genome-wide siRNA 
screen, we characterized the migratome of primary human LECs and identified individual 
genes and signaling pathways that regulate LEC migration. We compared our dataset 
with mRNA differential expression data from endothelial and stromal cells derived from 
two in vivo models of lymphatic vessel remodeling, viral infection and contact 
hypersensitivity-induced inflammation, which identified genes selectively involved in 
regulating LEC migration and remodeling.  We also characterized the top candidates in 
the LEC migratome in primary blood vascular endothelial cells to identify genes with 
functions common to lymphatic and blood vascular endothelium. Based on these 
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analyses, we showed that LGALS1, which encodes the glycan-binding protein Galectin-1, 
promoted lymphatic vascular growth in vitro and in vivo and contributed to maintenance 
of the lymphatic endothelial phenotype. Our results provide insight into the signaling 
networks that control lymphangiogenesis and lymphatic remodeling and potentially 




The lymphatic vasculature is a unidirectional system of vessels with essential roles in 
normal and pathological physiology. The endothelial cells (ECs) lining lymphatic vessels 
regulate many of these functions, including fluid resorption, secretion of proteins into 
lymph fluid (1), and interaction with immune cells (2). Sprouting growth 
(lymphangiogenesis) and remodelling of lymphatic vessels are essential during both 
embryonic development of the differentiated lymphatic vasculature and in adult 
pathological contexts such as wound healing, inflammation, immune responses and 
cancer (3, 4). During immune responses, growth and remodelling of lymphatics at the 
primary site and its draining lymph node (LN) enhance trafficking of dendritic cells, with 
implications for generating effective antigen-specific immune responses (2, 3). In cancer, 
however, increased lymphatic vessel density in tumours is correlated with disease 
progression and decreased survival (4), indicating that expansion of the lymphatic 
vasculature enables metastatic spread of tumour cells to the draining LNs and potentially 
to distant organs (1, 5, 6). The sprouting growth, remodelling, and early developmental 
separation and differentiation of lymphatics, all require coordinated migration of 
Comment [WW2]: WW to authors: Had 
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lymphatic endothelial cells (LECs) (7, 8). 
Cell migration requires the complex coordination of multiple individual processes within 
and between cells (9, 10), including extension and depolymerisation of actin- and tubulin-
comprised cytoskeletal structures, formation and vesicular recycling of adhesion 
complexes, and regulatory signal transduction in response to guiding stimuli. To better 
understand the complex signalling networks regulating cell migration, and to discover 
previously unidentified components, several groups have conducted RNA interference 
screens in various cell types using the scratch wound assay of collective cell migration 
(11-15). Whilst these studies have successfully identified genes and signalling networks 
that regulate cell migration in vitro, the findings are not often validated in diverse 
experimental systems, and the relevance of these findings to human disease is rarely 
directly explored. Although various signalling pathways have been identified as key 
drivers of LEC migration through various experimental systems, including the vascular 
endothelial growth factor (VEGF) pathways involving VEGFC, VEGFD, VEGFR3 and 
Neuropilin 2 (NRP2) (8, 16-19), the broader lymphatic endothelial “migratome” remains 
unmapped and represents an untapped pool of potential therapeutic targets for controlling 
lymphangiogenesis. 
Here we describe an unbiased siRNA functional screening approach aimed at 
understanding the LEC migratome. As well as successfully identifying genes that have 
already been linked to cell migration or vascular development, the screen also identified 
genes not previously associated with cell migration or lymphatic biology. Knockdown of 
the validated gene set in blood vascular endothelial cells (BECs) identified subsets of 
genes that had either common or distinct roles in each EC type. Comparison with 
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microarray data derived from two in vivo models of lymphatic growth and remodelling 
confirmed the biological relevance of several of these genes and the screen globally. 
Futhermore a particular candidate, LGALS1 (encoding Galectin-1; Gal-1), played a role in 
regulating lymphangiogenesis and LEC phenotype. This study provides insight into the 
signalling networks that control the migration of both lymphatic and blood vascular ECs, 
and has identified a pool of potential new therapeutic targets.  
 
Results 
A genome-wide siRNA screen identifies high confidence genes required for LEC 
migration. 
To identify genes and signalling pathways that regulate migration of LECs we have 
conducted a genome-wide siRNA functional screen involving 18,120 SMARTpools 
targeting protein-coding genes using primary human dermal microvascular neonatal 
lymphatic endothelial cells (HDLECs) (fig. S1, A to C; Data File S1). We have published 
a technical description of this screen and deposited the datasets in publicly accessible 
databases (20). Using high-throughput cell culture robotics, microscopy and image 
analysis, this screen measures the migration of siRNA-transfected HDLECs into a scratch 
wound created in the cell monolayer (15) (Fig. 1A; fig. S1, D to G; S2, A to F; S3). 
Genes that impair cell proliferation and viability rather than migration are identified using 
nuclear counting, and 438 genes classified as “Low Cell Count” are thus excluded from 
further analysis in the migration screens (Fig. 1B). This list included FLT4, encoding 
VEGFR3, which is central for LEC growth and survival, as well as several genes 
encoding other growth factor receptors and key downstream signalling kinases such as 
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PI3K.  
Quantification of the wound area covered by migrating cells after 24 hours (fig. S2, E and 
F) relative to mock-transfected controls provides an index of cell migration capacity, 
which is then normalized to generate z scores (21). A threshold of |robust z score| >2 (a 
robust z score >2 or <−2, representing the top and bottom 2.3% of scores) is used to 
identify biologically and statistically relevant candidate genes for further rounds of 
screening  (20). Consequently a total of 650 genes have been classified with regard to 
siRNA-mediated migration outcome as “Impaired” (robust z score <-2), and 385 as 
“Accelerated” (robust z score >2; Fig. 1B).  
To technically validate the results of the primary screen 500 candidate genes have been 
analysed in a secondary screen in which the four component siRNAs of the SMARTpools 
are assayed individually (20). The list comprises 401 “Impaired” and 99 “Accelerated” 
candidates, curated according to highest robust z scores, greater expression in lymphatic 
than in blood endothelium, and protein-protein interactions with the products of other 
candidate genes. The greater representation of “Impaired” compared to “Accelerated” 
candidates reflected the higher representation of the “Impaired” phenotype in the primary 
screen, and our focus on identifying positive regulators of HDLEC migration 
(knockdown of which would generate an “Impaired” phenotype).  The secondary screen 
has validated 154 genes with medium to high confidence (with 2-4 duplexes reproducing 
the primary screen phenotype) (Data File S2). All of these candidates impair cell 
migration when knocked down. For a further 5 “Accelerated” and 117 “Impaired” 
candidates from the primary screen, the original phenotype was reproduced 
unambiguously by only 1 of the 4 individual siRNAs (Data File S2); these genes were 
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considered to be validated with low confidence. The higher rate of validation for 
“Impaired” than “Accelerated” phenotypes highlighted the selectivity of our assay system 
for identifying positive regulators of HDLEC migration, but may also indicate that 
relatively more genes expressed in HDLECs function to promote than to restrict 
migration.  
To determine the biological relevance of the genes identified in the first two stages of the 
siRNA screen, we subsequently assessed the data at multiple levels to identify important 
genes and signalling networks (Fig. 1C). At the most stringent level, the 154 genes 
validated in the secondary screen – the “highly-validated” migration candidates – were 
carried forward into a tertiary screen to assess their effects on cell morphology and in 
blood vascular ECs, as well as more detailed functional cell biological analyses. The 
1035 genes with |robust z score| >2 in the primary screen - the “migration candidates” – 
provided a broader analysis of signalling pathway and gene ontology (GO) enrichment. 
Finally, the “expanded migration candidate” gene set, including all genes from the 
primary screen with |robust z score| ≥1.6449 (representing the top 5% and bottom 5% of 
robust z scores), was used for comparison to independent in vivo-derived datasets.  
 
Candidate migration genes in lymphatic endothelium are associated with EC biology, 
migration and key signalling networks. 
Signalling pathway enrichment analysis of the “migration candidates” (|robust z score| 
>2) showed that these were significantly over-represented in pathways related to 
cytoskeleton remodelling and development (Data File S3). Analysis of gene ontology 
(GO) processes also revealed over-representation of genes assigned to terms such as 
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“regulation of endothelial cell migration” and “regulation of positive chemotaxis”, as 
well as terms broadly associated with phosphorylation and signalling (Data File S4). The 
range of impaired migration phenotypes indeed suggested that multiple different cell 
processes had been perturbed (fig. S1G).  
We grouped the “highly-validated” migration candidate genes into functional categories 
based on GO terms and previous studies describing their known or proposed role in the 
cell using the Metacore database (Fig. 2). Mapping to GO processes showed that many of 
these 154 candidates were linked to specifically relevant terms such as “locomotion” 
(~23% of the candidates), “response to wounding” (~23%), “cell migration” (~17%) and 
“vasculature development” (~15%) (Data File S5). Enrichment analysis also revealed 
statistically significant over-representation in pathways linked to cytoskeleton 
remodelling, cell adhesion and VEGF-driven signalling cascades (fig. S4, Data File S6). 
Ten “highly-validated” HDLEC migration genes had been previously associated with 
canonical aspects of cytoskeletal remodelling or migration pathways (AKT3, GNAS, 
IL1B, JUN, LIMK1, PDGFRB, PLCG1, MYL7, CALM2 and CDC42; Data File S6). 
Developmental signalling pathways were also over-represented, including signalling 
cascades downstream of FGF and PDGF receptors and growth hormone and 
erythropoietin (EPO) signalling pathways, which have been previously reported to be 
important for lymphatic vessel growth (22, 23). The receptor tyrosine kinase PDGFRβ 
and the growth factor ANGPT2 have also been defined as regulators of 
lymphangiogenesis (24, 25), thus further emphasizing the ability of the screen to identify 
biologically relevant genes.  
Other signalling pathways over-represented in the “highly-validated” gene set included 
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those connected to directed migration of neuronal sprouts (axon guidance); and the 
immune response, reflecting the interconnectedness of lymphatic remodelling and 
immunity (Data File S6). Components of inositol phosphate and glycerophospholipid 
metabolism pathways were also enriched (Fig. 2 and fig. S4), supporting the importance 
of these molecules in signalling pathways leading to cell migration (26). 
 
Morphology analysis gives insight into function of highly-validated genes in cell 
migration. 
The process of cell migration affects cell morphology due to dynamic remodelling of the 
cytoskeleton and regulation of cell-substrate adhesion (10, 14). To gain further insight 
into the specific subcellular functions of the 154 “highly-validated” migration candidate 
genes, images of the respective siRNA-transfected cells have been analysed in a tertiary 
screen to assess various cellular and cytoskeletal parameters, including area and other 
dimensional measurements (indicative of cell-substrate adhesion and spreading), cell 
shape (reflecting spreading or lateral polarisation), average actin intensity (reflecting 
overall abundance of filamentous actin) and actin texture (variability in intensity, 
reflecting discrete actin structures) (Fig. 3, A and B) (20). Distinct morphological 
changes in siRNA-transfected HDLECs were visibly evident in images of the cell 
monolayers 24 h post-wounding (Fig. 3C, fig. S5A). Hierarchical clustering of the 
normalized morphology parameter datasets has identified six clusters of gene-specific 
siRNA SMARTpools that induce similar morphological phenotypes (Fig. 3, B and D; fig. 
S5A and B; Data File S2).  
Silencing of genes in cluster 1 did not significantly alter HDLEC morphology compared 
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to mock transfected cells, suggesting that proteins such as PIK4A and PIK4B (Fig. 3D; 
Data File S2) regulate HDLEC migration in ways that do not influence morphology. In 
contrast, knockdown of genes such as  IL1B, MICAL2, GPR84 and LGALS1 in cluster 2 
led to cells that were more elongated, and had increased and uniform actin staining (Fig. 
2, B to D; Data File S2). Galectin-1 (encoded by LGALS1) disturbs the integrity of the 
cortical cytoskeleton (involving a decrease in VE-cadherin-mediated cell-cell junctions) 
and promotes stress fibre formation in HUVECs by binding to NRP1 at the cell 
membrane and activating downstream Rho kinase signalling (27). A similar mechanism 
in HDLECs may explain the diffuse actin staining pattern typical of knockdown of genes 
in this cluster. Cluster 2 also included HOXC5, which encodes a transcription factor, 
PLCG1 and BTK (Fig. 3B to D; Fig. S5A, Data File S2). BTK and PLCγ2 regulate 
chemokine-controlled, integrin-mediated migration in B lymphocytes (28, 29), which 
likely involves the ability of BTK to promote actin nucleation and polymerization (30). 
The inhibition of this pathway in our HDLEC screen may thus be responsible for the 
observed migration and morphology phenotypes. Notably, knockdown of genes in cluster 
2 also resulted in significantly more impaired migration compared to knockdown of those 
in cluster 1, which did not alter morphology, thus highlighting the connection between 
cell morphology and migration (fig. S5C). 
Targeting of genes in cluster 6 led to cells that were more elongated, but also larger in 
area than control cells. This phenotype was characteristic of siRNA SMARTpools 
targeting CDC42 and the gene encoding the downstream kinase LIMK1 (Fig. 3, B and D; 
fig. S5A). Similarly, silencing of genes in cluster 3 such as ANGPT2 and EPOR led to 
larger cells with low average actin staining (Fig. 3, B and D; fig. S5A). ANGPT2 
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regulates developmental lymphatic migration and remodelling (25, 31), and triggers 
stress fibre formation at the expense of cell-cell junction integrity in BECs by activating 
integrin-β1 (32). EPOR (EPO receptor) can induce lymphangiogenesis when activated by 
EPO (23) or potentially through transactivation by VEGFA-activated VEGFR2 as is 
shown in blood vascular endothelium (33).  Other genes that clustered with this 
phenotype included carbohydrate sulfotransferases (CHST5, CHST8), cytoskeleton 
interacting proteins (FLCN, MYL7, and TUBA1B), and several uncharacterized genes not 
previously known to regulate cell morphology (C2orf28, C7orf55, C17orf59, C11orf63). 
Knockdown of genes in cluster 5 (which included SETD2 and KANSL1), increased cell 
area but did not affect actin intensity or distribution (Fig. 3B and D; fig. S5A). SETD2 is 
a histone H3 lysine 36 methyltransferase that has been implicated in remodelling of the 
embryonic vasculature (34). KANSL1 is also a component of a histone acetyl transferase 
complex (35), suggesting that these factors may control the expression of suites of genes 
involved in regulating EC size and migration. Lastly, knockdown of genes in cluster 4 
such as TPST2, RTKN and JUN led to elongated cells, with lower intensity actin staining 
but higher texture difference of actin staining, potentially indicating stress fibre formation 
(Fig. 3B and D; fig, S5A). TPST2 encodes a tyrosylprotein sulfotransferase that is 
activated in ECs under shear stress conditions (36), while RTKN regulates actin 
remodelling pathways by inhibiting the GTPase activity of Rho family proteins (37). JUN 
encodes the AP-1 transcription factor subunit c-Jun, which is annotated to multiple 
signaling pathway and processes related to cell migration (Data Files S3 and S6). For 
example, it promotes sheet migration of epithelial cells through inducing transcription of 
pro-migratory factors such as EGF (38). 
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Screening of BEC migration reveals common regulators of EC migration and 
identifies distinct migration machinery in LECs. 
To understand the conservation of functional pathways between different EC types, the 
“highly-validated” migration candidates have been reassessed in a tertiary siRNA screen 
for migration effects in both human microvascular blood endothelial cells (HMBECs) and 
HDLECs (Fig. 4A) (20). To minimise differences due to vessel calibre or anatomical 
location, HMBECs isolated from neonate dermis are used to match the source of the 
HDLECs. HMBECs lacked the LEC molecular markers PROX1, Podoplanin and LYVE1 
but produced more von Willebrand factor (fig. S6A; compare to fig. S1, B and C) (39). 
The migration of primary HMBECs in the scratch wound assay was faster than HDLECs, 
such that the wound was 50% closed after 16 h (fig. S6B).  
The similarity of the siRNA target-specific phenotypes between the two cell types was 
high, despite the difference in wound closure dynamics. Using a cut-off of <65% of 
mock-transfected cell migration, 111 of the 154 siRNA pools have resulted in impaired 
migration in at least one cell type (Fig. 4A). The comparison demonstrated that while a 
substantial portion (61.3%) of the gene candidates derived from the genome-wide 
HDLEC migration screen also affected HMBEC migration, a subset had cell-type 
specific effects (Fig. 4, A and B; Fig. S7, A to C). Analysis of the HMBEC migration 
screen results allowed grouping of candidate genes into 68 “Common EC” migration 
genes important for the migration of both EC types, 23 “BEC dominant” genes with a 
greater effect on the migration of HMBECs, and 20 “LEC dominant” genes with a greater 
effect on HDLECs (Fig. 4, A and C, Data File S2). 
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The morphological attributes of the siRNA-transfected HMBECs largely resembled those 
of the HDLECs (Fig. 4D, compare to Fig. 3B). This result not only confirmed the 
robustness of the morphological changes observed, but further emphasized the functional 
importance of these genes for both cell types. The clustering of genes with similar 
morphological phenotypes suggested possible inter-connected signalling pathways 
controlling specific aspects of cytoskeletal remodelling and cell migration. However, 
there were also some differences between the morphologies caused by gene silencing in 
HMBECs and HDLECs (Fig. 4, C to E; fig. S7, A to C).  For example, silencing of SGK3 
in HMBECs caused an increase in cell size and elongation that was not seen in HDLECs 
(fig. S7, A and C) and inhibited migration more strongly than in HDLECs (Fig. 4C). 
Silencing of CDC42 in HMBECs did not result in a decreased shape factor (namely 
elongation; fig. S7, B to C). This finding supported the increased impairment of 
migration by CDC42 silencing in HDLECs compared to HMBECs (Fig. 4, B and C; Data 
File S2), emphasizing the differential function of this protein in the different cell types. 
Assessment of lymphatic (CEACAM-1, identified by microarray analysis as HDLEC 
enriched) and blood (CD146) EC marker abundance after depletion of CDC42 or LIMK1 
confirms the linkage of these differential effects to each distinct cell lineage (fig. S7D). 
LPL siRNA also led to impaired migration and elongated morphology (reduced shape 
factor) in HDLECs but not in HMBECs (Fig. 4, C to E). Lipoprotein lipase (LPL) is 
important for the hydrolysis of lipoproteins (for example low-density lipoprotein) to fatty 
acids, and their uptake into cells (40). This cell-type specific effect may reflect the 
important role that the lymphatics play in absorption of fatty acids from the gut, and a 
role for LPL in LEC migration could relate to the association between lymphatic function 
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and fat deposition (1). Knockdown of LPL inhibits migration of glioma cells (41), an 
effect that may relate to its interaction with heparan sulfate proteoglycans that are closely 
linked with components of the actin cytoskeleton (42). Furthermore exogenous LPL 
regulates inflammatory responses in aortic ECs, suppressing TNFα-induced gene 
expression by activation of IκBα whilst enhancing IFNγ-induced gene expression (43).  
 
Identification of genes involved in LEC migration enables construction of a migration 
signalling network. 
To better understand the molecular mechanisms required for EC migration, we utilized a 
protein–protein interaction database (Metacore) to map the signalling pathways of the 
genes identified in our screen. Construction of a signalling network using both “Common 
EC” migration genes and “LEC dominant” genes demonstrated that many of these 
proteins were closely connected (Fig. 5). Indeed, some of these molecules were key 
nodes of the EC migratome network (such as PLCG1, JUN, and PDGFRB). The network 
also revealed connections with various proteins associated with predominant migration 
phenotypes in HDLECs. These included CDC42, PPP1CA and BTK, which were 
identified as LEC nodal signalling points, suggesting that they may play central roles in 
coordinating migration signalling in LECs. The network also provided insight into anti-
migratory signalling pathways. While much of the positive signalling (Fig. 5, green lines) 
converged on PLCG1, CDC42 and PPP1CA, inhibitory signals (Fig. 5, red lines) passed 
through GSK3B. Indeed, this is consistent with the role of GSK3B as an inhibitor of key 
cellular functions such as protein translation and motility (44). 
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Candidate genes identified by siRNA screening overlap significantly with genes 
differentially expressed during lymphatic remodelling in vivo. 
We next sought to validate that our functional in vitro siRNA screen had identified genes 
that were also relevant in pathological lymphangiogenesis in vivo. To this end, we 
compared the primary siRNA screen results to a list of genes that are differentially 
expressed in remodelling lymphatic endothelium from an in vivo model of viral infection 
(45). Sprouting growth and remodelling of both lymphatic and blood vascular networks 
in LNs downstream of an infection site is integral to supporting effective immune 
responses (3, 45). LECs, BECs and fibroblastic reticular cells (FRCs) are freshly isolated 
from LNs six days after cutaneous infection with Herpes Simplex Virus (HSV)-1 and 
their expression profiles as determined by microarray analysis compared to those of 
equivalent cell populations from uninfected (day 0) controls (45). We further applied a 
fold-change threshold (day 6 compared to day 0) of ≥ |1.8| to enrich for genes whose 
mRNA abundance had changed to a degree that would suggest a functional biological 
consequence. The “expanded migration candidate” list from the siRNA screen (|robust z 
score|  ≥ 1.6449) was selected for comparison to the microarray results. siRNA targets 
with a robust z score of 1.6449 in the primary screen had migration scores approximating 
145% of the median (“Accelerated”), whilst a robust z score of -1.6449 corresponded to 
migration scores of ~55% of the median (“Impaired”). Genes classified as “Low Cell 
Count” were excluded as previously to focus the analysis on genes involved in migration. 
This expanded list was generated to potentially enable retrieval of candidates for which 
the conditions of the in vitro assay did not capture maximal functional impairment, and to 
accommodate differences in species, timeframe, stimulation factor and output 
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measurement between the two experimental systems.   
Five days after infection, all cell subpopulations in the LN had expanded, and lymphatic 
growth and remodelling were evident (Fig. 6A) (45). The list of genes differentially-
expressed in LN LECs at day 6 (both increased and decreased in day 6 compared to day 0 
LNs) was tested for size and significance of overlap with the “expanded migration 
candidate” list from our migration screen using simulated null distributions (Fig. 6B) and 
hypergeometric distributions.  This analysis revealed a statistically significant overlap of 
133 genes common to the siRNA screen and LN microarray results (Fig. 6, B and C; D, 
row labelled “LEC total”; Data File S7). These included several genes validated in the 
secondary and tertiary siRNA screens, including LGALS1, COPB2, and ANGPT2. The 
statistical significance of this overlap was supported by the more conservative estimates 
given by hypergeometric analysis (Fig. 6D). A similar analysis of genes commonly 
differentially regulated in both LN LECs and BECs showed a significant overlap of 20 
genes (Fig. 6D, “EC-common total”; Data File S7). 
To better determine the ability of the siRNA screen to identify genes selectively involved 
in LEC migration, the microarray data was filtered to create lists of genes selectively 
differentially-expressed in LECs, BECs and FRCs. Genes were designated as “selective” 
for a given cell type or types (with reference to the day 6 timepoint and the three cell 
types analysed) if they were significantly differentially-expressed over the 1.8-fold 
threshold only in that cell type or types whilst being unchanged or differentially-
expressed in the opposite direction in the other cell types. Lists of EC-selective 
differentially-expressed genes (those differentially-expressed in both BECs and LECs but 
not FRCs); and genes differentially expressed in all cell types (Fig. 6D) were derived 
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according to the same criteria. The LEC-selective differentially-expressed gene list 
overlapped significantly with the “expanded migration candidate” list, revealing 90 genes 
that were identified above the respective thresholds in both experiments (Fig. 6, D and E; 
Data File S7). This included “highly-validated” genes such as EPOR, SMURF2 and 
USP25, mapped within the LEC migration signalling network (Fig. 5), and MICAL2, a 
less extensively characterised gene. Comparison of the siRNA screen results to EC-
selective differentially-expressed genes also revealed a statistically significant overlap 
(Fig. 6D and E). In contrast, overlap with BEC-selective gene lists and genes commonly 
regulated in all cell types was not statistically significant (Fig. 6D).  
As additional validation, we used the same method to compare the expanded migration 
candidate list to an independent publicly-available microarray dataset derived from 
mouse ear dermal LECs in a model of contact hypersensitivity (CHS; 46). In this model, 
mice are first sensitised to oxazolone, then a CHS (delayed-type hypersensitivity) 
reaction is induced by topical application of oxazolone to the ears.  This treatment results 
in expansion and remodelling of the lymphatic network at the site of the second 
oxazolone challenge, beginning within 24 hours (47). The list of genes that were 
differentially-expressed in CHS-activated compared to unstimulated LECs 24 hours post-
challenge also overlapped significantly with our expanded migration candidate list (Fig 
6F; Data File S8). Il1b mRNA was highly increased in expression in CHS-derived LECs, 
and its human ortholog was an EC common migration candidate (Fig. 5; Data File S8). 
IL1B is an inflammatory cytokine which induces cell-surface presentation of leukocyte 
adhesion molecules and impaired barrier function in LECs (48, 49). Furthermore IL1B 
may indirectly promote lymphangiogenesis by increasing autocrine or paracrine 
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production of VEGFC or VEGFA, and VEGFR2 in endothelium (50, 51). Overall, these 
analyses further validate the biological relevance of the siRNA screen by illustrating its 
selective ability to identify genes with enriched importance in LECs, and confirming that 
these genes are implicated by other methods in pathological lymphatic remodelling in 
vivo, both in dermal settings and in other relevant tissues.   
 
In vitro and in vivo assays of lymphangiogenesis and lymphatic remodelling identify 
Galectin-1 as a regulator of LEC function and phenotype  
We next sought to confirm the role of our “highly-validated” migration candidates in 
LEC migration, remodelling and lymphangiogenesis. LGALS1 and MICAL2 (microtubule 
associated monoxygenase, calponin and LIM domain containing 2) were also identified 
in the LN remodelling microarray analysis, and exhibited the highest fold-change in 
expression in LECs (with the exception of the well-characterised ANGPT2). MICAL2 
served as a representative candidate that was selectively differentially-expressed in LECs 
in the LN microarray analysis, whereas LGALS1 was the only “highly-validated” gene 
differentially-expressed in both LN EC types (Data File S7).   
Galectins are a family of widely-distributed, secreted glycan-binding proteins with roles 
in regulating cell-cell adhesion and signalling in diverse biological processes, including 
angiogenesis and immune cell trafficking (52). Western blot analysis showed abundant 
Gal-1 protein in HDLECs, comparable to its abundance in HMBECs (Fig. 7A). Silencing 
of LGALS1 efficiently reduced Gal-1 protein in HDLECs (Fig. 7, B and C), and 
significantly impaired HDLEC migration in the scratch wound assay (fig. S8A), 
recapitulating the migration phenotype observed in the screens. Further, silencing of 
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LGALS1 in a collagen overlay tube formation assay demonstrated that Gal-1 was also 
required for proper HDLEC tubule remodelling (Fig. 7D, fig. S8B). LGALS1 knockdown 
led to significantly reduced tubule area and thickness, and qualitative failure to establish a 
network. In an alternative tubule formation assay, Gal-1 knockdown also reduced average 
tubule length, size, total junctions and total tubule length of HDLECs cocultured with 
fibroblasts (Fig. 7 E to G and fig. S8C). Similarly knockdown of MICAL2, but not the 
related MICAL1 (fig. S9C), impaired LEC scratch wound healing (fig. S9, A, B and F) 
and tubule formation (fig. S9 D to E and G to H), without affecting monolayer integrity 
or pan-endothelial identity as determined by VE-cadherin at intercellular junctions (fig. 
S9F). These findings are consistent with the roles of MICAL family proteins in migration 
and morphogenesis through depolymerisation of actin (53). Together, these results 
provide further evidence that both MICAL2 and Gal-1 promote LEC migration and 
vessel assembly. 
An important aim of this study was to identify potential targets for therapeutic control of 
pathological lymphangiogenesis and lymphatic remodelling. Gal-1 mediates resistance to 
VEGFA-targeted anti-angiogenic cancer therapies, related to its promotion of BEC 
migration by potentiating VEGFA signaling through NRP1 and VEGFR2 (54, 55). It also 
regulates cell-cell and cell-matrix interactions more broadly, and hence is furthermore 
implicated in cancer metastasis and immune cell trafficking (52, 56).  Indeed, targeting of 
Gal-1 using inhibitory antibodies or the Gal-1-directed inhibitory peptide Anginex can 
reduce VEGFA-dependent angiogenesis and tumour growth, as well as altering 
recruitment of certain leukocyte subsets (55, 57, 58). Thus, targeting Gal-1 in cancer 
could potentially restrict multiple aspects of tumour progression, including 
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lymphangiogenesis which is associated with metastasis, and angiogenesis that promotes 
tumour growth. As further evidence for its role in pathological lymphangiogenesis, 
Lgals1 mRNA is increased up to 5-fold (unlike Mical2 mRNA, which was decreased) in 
LECs from inflamed compared to normal ears in the independent CHS microarray dataset 
(unadjusted p value = 0.0123) (46).  
To validate whether Gal-1 also regulated lymphatic vessel remodelling in vivo, we 
injected mouse ear skin with Gal-1 protein. Ears injected with Gal-1 exhibited both a 
significantly increased lymphatic vessel density and a 30% increase in vessel width 
compared to control (Fig. 7H). This increase was abrogated by the addition of the Gal-1-
inhibitory peptide Anginex (Fig. 7H). In confirmation, an in vitro assay of 
lymphangiogenic sprouting from explants of thoracic duct (the major lymphatic trunk) 
revealed enhancement of lymphangiogenic sprouting by exogenous Gal-1 protein and 
inhibition of VEGFA-induced lymphangiogenesis by Anginex (fig. S8, D and E). Gal-1 
also promoted an increase in CD146-positive blood vessel density in our mouse ear skin 
model (fig. S10A; Fig. 7H). In an aortic ring explant assay, Anginex inhibited VEGFA-
induced angiogenic (BEC) sprouting, although promotion of sprouting by Gal-1 did not 
reach statistical significance (fig. S10, B and C). Overall, our data suggest that targeting 
Gal-1 may also be effective at inhibiting tumour-associated lymphangiogenesis or 
lymphatic remodelling. 
In human LN tissue, immunohistochemistry showed that Gal-1 was localized to the 
endothelium of lymphatic vessels as defined by co-staining with Podoplanin (Fig. 7I). 
This distribution pattern also validated the detection of Lgals1 mRNA by microarray in 
the Podoplanin+CD31+ LECs isolated from mouse LNs, as well as in purified LN BECs 
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and FRCs (Data File S7). Furthermore, bioinformatic data-mining of the Oncomine™ 
database revealed a significant increase in LGALS1 mRNA expression in tumour stroma 
from patients with invasive breast cancer (Fig. 7J). Collectively our data point to a role 
for Gal-1 in promoting lymphangiogenesis and lymphatic remodelling, with potential 
clinical implications. 
Based on the potentiation of VEGFR2 signalling by Gal-1 in BECs (55, 59), we next 
examined whether Gal-1 depletion influenced HDLEC responses to VEGFA. Compared 
to control-transfected LECs, HDLECs transfected with LGALS1 siRNA exhibited 
enhanced VEGFR2 phosphorylation at Tyr1175 (required for downstream MAPK 
signalling (60)) when stimulated with VEGFA, along with significant increases in 
phosphorylated ERK2 and AKT (Fig. 8, A and B). Phosphorylation of Src family kinases 
after VEGFA stimulation was slightly but not significantly increased in Gal-1-depleted 
HDLECs (Fig. 8A; fig. S11, A and B). Gal-1 abundance in LGALS1-depleted and Control 
HDLECs remained relatively constant over the timecourse (fig. S11C). Whilst VEGFC, 
but not VEGFA, induced phosphorylation of VEGFR3 as expected (fig. S11D), total 
VEGFR3 abundance was decreased in Gal-1-depleted HDLECs, irrespective of VEGFA 
stimulation (Fig. 8C). Because VEGFR3 abundance is decreased in BECs postnatally, but 
maintained at high amounts in LECs (61) (fig. S11E), this result suggested a switch 
toward a BEC phenotype. 
To explore this notion further, we next assessed LGALS1 siRNA-targeted HDLECs for 
mRNA and protein of typical LEC- and BEC- selective markers (Fig. 8, D to G; fig. 
S11F). Knockdown of LGALS1 was associated with reduced CEACAM1 
immunofluorescence and loss of cells with high LYVE1 immunofluorescence (these 
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being LEC markers), whereas the immunofluorescent signal for the VEGFR2 coreceptor 
CD146, which is more abundant in BECs than LECs (fig. S11E) (62, 63) was increased 
(Fig. 8D, fig. S12A). qRTPCR analysis confirmed significantly reduced expression of 
LYVE1 and increased expression of CD146 mRNA in LGALS1-depleted compared to 
control-transfected HDLECs (fig. S11F). This analysis also revealed a general trend 
towards decreased expression of mRNA encoding LEC markers (such as PROX1 and 
ITGA9) and increased expression of genes typically more abundantly expressed in BECs 
than LECs (such as TEK, which encodes TIE2, and CD146). This pattern was confirmed 
by Western blot analyses, which showed that compared to control-transfected HDLECs, 
LGALS1-depleted HDLECs exhibited significantly decreased abundance of LEC-
characteristic proteins VEGFR3, CEACAM1, Podoplanin and the central LEC identity 
regulator Prox1 (Fig. 8, E to G). In contrast, CD146 and VEGFR2, which are typically 
more abundant in BECs than LECs (Fig. S11E), were increased (Fig. 8, E to G). Notably, 
LGALS1 siRNA induced a greater increase in CD146 protein than did siRNAs targeting 
SOX18 and CEACAM-1, both of which can induce LEC identity in ECs (Fig. 8, E to G; 
fig. S12, B and C) (64, 65). Given that lower abundance of Prox1, LYVE1, ITGA9 and 
VEGFR3 compared to initial (microvascular) lymphatics is also characteristic of large 
collecting lymphatic vessels (66), LGALS1 knockdown could possibly have induced 
HDLEC differentiation towards a collecting LEC phenotype, although high CD146 
abundance has not apparently been reported in collecting lymphatic endothelium. 
Interrogation of our microarray analysis of collecting vessel LECs (67) suggested that 
Cd146 was expressed at very low abundance in these cells (fig. S11G). Furthermore, 
LGALS1 depletion in HDLECs reduced the abundance of Podoplanin (encoded by PDPN 
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in humans and Pdpn in mice), a LEC marker expressed robustly in collecting lymphatic 
endothelium (fig. S11G) (67). Our data therefore suggest that loss of endogenous 
LGALS1 expression induces differentiation of HDLECs towards a blood vascular 
phenotype. LGALS1 siRNA-treated HDLECs also maintained CDH5 (VE-cadherin) cell-
cell contacts at the wound border that were typically diminished during migration in 
control-treated HDLECs (Fig. S13A). This corroborated the inhibitory effect of Gal-1 on 
migration and confirmed, alongside CD31 staining, that endothelial cell identity was 
maintained (fig. S13, A to B). Together, our results indicate that Gal-1 not only promotes 
HDLEC migration and remodelling, and modifies VEGFR2 signalling, but also 
contributes to the maintenance of the lymphatic endothelial phenotype. 
 
Discussion 
EC migration is a critical component of sprouting vessel growth and vessel remodelling 
during development and disease. The scratch wound assay provides a tractable and 
relevant in vitro model of angiogenesis, as it can replicate both “pioneer” and “follower” 
modes of migration (13), with potential analogy to “tip” cells and “stalk cells” in three-
dimensional angiogenesis (9). Previous siRNA and shRNA screens for regulators of 
migration in epithelial and endothelial cells cover only a subset of the genome (11-13), 
while one screen in a fibroblast cell line has interrogated the full genome (68). Our 
whole-genome approach has revealed multiple signalling pathways and individual genes 
that control collective migration in a specialized primary human lymphatic EC, the 
HDLEC.  
Of the 154 highly-validated candidate migration genes a proportion have well-
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characterised roles in migration across various cell lineages, such as the small GTPase-
encoding CDC42 (69). Further confirmation of the effectiveness of the screen was the 
high confidence validation of genes with known roles in LEC biology, such as ANGPT2, 
which encodes a ligand for the TIE2 (TEK) receptor. In mice lacking Angpt2, lymphatic 
filopodial sprouting is impaired, and the primary lymphatic plexus fails to remodel into 
the mature lymphatic hierarchy (25, 31). Furthermore, ANGPT2 promotes tumour 
lymphangiogenesis (70, 71). Angpt2 expression was selectively increased in LN LECs 
during viral-induced remodelling (Data File S7), indicating that it may promote 
lymphangiogenesis in multiple adult pathological settings. 
The biological validity of our siRNA screen was also confirmed by substantial global 
overlap of our candidate genes with those identified by differential expression in 
microarray analysis of viral-induced or CHS-associated lymphatic remodelling (Fig. 6). 
The identification of overlapping genes across differences in species, biological and 
experimental context, measurement methodology and timeframe gives confidence to their 
biological relevance in LECs. Genes that were highly validated in the siRNA screens but 
not detected as differentially expressed in the in vivo models may represent those that are 
functionally important but are expressed in constant amounts during LEC migration and 
remodelling. Furthermore, our in vitro migration screen provided evidence of specific 
gene function that the in vivo microarray analysis alone could not. Notwithstanding that 
many genes are multifunctional, our screen enabled distinction of siRNA targets that 
primarily influence proliferation or survival from those chiefly regulating migration. 
Other siRNA screens using the scratch wound migration assay confirm that cell 
proliferation does not contribute substantively to wound closure (12, 13). Together, these 
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analyses suggest that our screening approach identified genes that are relevant to 
pathological lymphangiogenesis that can be further investigated.  
Our siRNA screen uncovered both common and distinct gene functions in LECs and 
BECs, including some genes that are considered important central regulators of cell 
migration. Targeting of CDC42 and LIMK1 impaired HDLEC migration, but only mildly 
inhibited HMBEC migration. Similarly, silencing of CDC42 caused morphological 
changes in HDLECs that were not seen in HMBECs. This suggests that Rho family 
GTPases (and their downstream effectors) are differentially regulated in these two related 
cell types, possibly by the adaptor molecule Afadin (72). Knockdown of certain key 
migration genes such as WASF2 and PTK2 in HDLECs resulted in lowered cell count, 
obscuring an observable migration effect. That RHOA and RAC1 were not identified in 
this screen may reflect insufficient gene silencing or functional depletion; however, it is 
also possible that these genes may be redundant and therefore not functionally required 
for migration in HDLECs. For example, RHOC expression was selectively increased in 
remodelling LN LECs (Data File S7) and its knockdown generated moderate inhibition of 
migration in the primary screen. Notably, a considerable subset of the candidate genes 
identified have not previously been associated with cell migration, thus representing an 
untapped resource for future studies to identify new gene functions.  
siRNA targeting of several genes (KANSL1, USP25, UGT1A7 and C7orf55) reduced the 
cell density of HMBECs but not HDLECs. These differences may be critical in 
optimizing the therapeutic targeting of either, or both, EC types. Indeed, genes classified 
in our screens as “Low Cell Count” may represent important regulators of survival, 
proliferation and adhesion. Understanding signalling pathways that trigger EC death may 
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be important for chemotherapy or radiation therapy in the context of cancer, and as such 
warrants further investigation. 
A goal of this siRNA screen was to identify new therapeutic targets for controlling 
pathological lymphangiogenesis. To this end, we demonstrated that LGALS1 and 
MICAL2 are required for HDLEC migration and tube formation. We further confirmed 
the importance of Gal-1 in supporting LEC migration, remodelling and in vivo 
lymphangiogenesis. Gal-1 also has an immunological function in the lymphatics in 
preferentially inhibiting the transmigration of immunogenic rather than tolerogenic 
dendritic cells into lymphatic vessels (56). A related molecule, Galectin-8, promotes 
VEGFC-induced lymphatic sprouting and pathological corneal lymphangiogenesis (73, 
74). This effect is independent of VEGFR3 and is mediated instead by Podoplanin and 
α1β1 and α5β1 integrins, in spite of direct interaction of Galectin-8 with VEGFR3. In 
contrast, Gal-1 does not potentiate VEGFC-induced sprouting (73). In our study Gal-1 
promoted VEGFA-induced lymphangiogenesis and lymphatic remodelling through 
VEGFR2. In BECs, Gal-1 promotes VEGFR2-mediated pro-angiogenic signalling by 
binding to specific branched N-glycans on VEGFR2 and/or its coreceptors NRP1 (54) 
and CD146 (59, 75-77). Dimeric Gal-1 can effectively cross-link the receptor complex, 
thereby inducing VEGF-independent signalling and also increasing retention of receptors 
on the cell surface, thus prolonging VEGFA-induced signaling (55). Accordingly, we 
showed that inhibition of Gal-1 activity by siRNA or Anginex impaired 
lymphangiogenesis (Fig. 7; fig. S8). Possible mechanisms of this effect include 
interfering with Gal-1-mediated potentiation and prolongation of VEGFR2 signaling 
and/or blocking Gal-1-mediated interactions with the extracellular matrix (54). Anginex 
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also binds to Galectins -2, -7, -8N and -9N (78). The role of Gal-1 in promoting 
lymphangiogenesis was evident in models of Gal-1-mediated lympangiogenic sprouting 
(thoracic duct explants) and in circumferential expansion of lymphatic vessels (mouse ear 
model), both of which may involve some LEC proliferation as well as migration given 
the importance of VEGFR2 signalling in both these processes (18, 79). Whilst CD146 
and NRP1 have been implicated in Gal-1’s pro-angiogenic activity in BECs, these 
receptors are typically much less abundant in LECs (62), which suggests that Gal-1’s 
activity on LECs may be predominately mediated through its interaction with VEGFR2, 
and/or through an alternate receptor yet to be defined. Candidate coreceptors in LECs 
might include NRP2, or integrins such as α1β1 which are required for VEGFA-induced 
LEC migration (79). 
While exploring the role of Gal-1 in LEC responses to VEGFA signalling we observed 
that LGALS1-depleted HDLECs had increased protein abundance of VEGFR2 and its co-
receptor CD146. The HDLECs apparently were concomitantly sensitised to VEGFA 
signalling through VEGFR2, showing enhanced phosphorylation of the receptor and its 
downstream signalling effectors ERK2 and AKT at 10 minutes after addition of VEGFA 
(Fig. 8, A to B). This enhanced VEGFR2 signaling in LGALS1-depleted HDLECs may be 
a consequence of increased VEGFR2 and CD146 protein abundance. However, the 
absence of Gal-1’s crosslinking effect could also accelerate VEGFR2 internalisation and 
subsequent degradation upon VEGFA stimulation, leading to an amplified but shorter-
lived burst of VEGFR2-initiated signaling from endosomes (55, 60). Depletion or 
blockade of Gal-1 sensitises resistant tumours to VEGFA-blocking antiangiogenic 
therapy (55), likely by preventing the VEGFA-independent VEGFR2 signaling induced 
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by Gal-1-mediated receptor crosslinking, thus restoring VEGFA dependency in tumour 
ECs. Our data therefore indicate that Gal-1 could similarly influence the sensitivity of 
tumour lymphatics to VEGFA. 
Increased VEGFR2 abundance following LGALS1 knockdown in our HDLECs also 
appeared to be part of a broader alteration in LEC phenotype (Fig. 8). LGALS1 depletion 
decreased protein abundance (albeit modestly) of the master LEC identity regulator 
PROX1, of which a certain threshold amount is required to maintain LEC identity (80, 
81). Future studies will determine whether Gal-1 contributes to LEC specification during 
development, or in the phenotypic plasticity observed in some pathologies (82, 83).  
Given the association of Gal-1 with VEGFR2, it is possible that Gal-1 sustains LEC 
phenotype by regulating the balance between endogenous VEGFR2 and VEGFR3-
mediated signalling. VEGFC signaling through VEGFR3 engages in a positive feedback 
loop with PROX1 expression during mouse development and in cultured HDLECs (84), 
implicating this axis in LEC migration, proliferation and identity. Gal-1 stimulation can 
induce VEGFR3 phosphorylation in trophoblasts (85), but apparently not in HUVECs 
(54), which may be due to differences in receptor glycosylation (55). A tentative link 
between Gal-1 and LEC identity is also suggested by the reprogramming of BECs 
towards a lymphatic phenotype by Kaposi’s Sarcoma Herpesvirus (KSHV) infection (86, 
87), and the high abundance of Gal-1 in KS-infected cells (58). Alternatively, 
intracellular, glycan-independent functions of Gal-1 in Ras localisation or pre-mRNA 
processing could also be involved in this phenotypic change (88), invoking pathways 
potentially independent of the VEGFC/VEGFR3/Prox1 axis. CD146 could also be 
involved in the LEC phenotypic change; depletion of Gal-1 may remove an inhibitory 
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autocrine feedback loop resulting in increased CD146 abundance. However, several of 
the Gal-1 receptors present on BECs - CD146, NRP1, integrin α1β5 and VEGFR2 – are 
less abundant or absent on LECs, with some suppressed by PROX1 (89, 90). Therefore, 
while Gal-1 may have common functions in LECs and BECs with regard to endothelial 
migration and vessel formation, our data suggest that it may signal in LECs through other 
pathways that remain to be elucidated. 
Our findings, including the identification of several genes not previously implicated in 
migration and of cell type-specific effects of gene knockdown, elucidate future avenues 
for research into the biology of lymphatic endothelial cell signalling and anti-
lymphangiogenic therapeutic targeting. We also characterised Gal-1 as a positive 
regulator of LEC migration and lymphangiogenesis. Together with Gal-1’s roles in 
promoting tumour angiogenesis and its implication in promoting a tolerogenic immune 
environment (52, 56), our data therefore present a rationale for targeting Gal-1 to inhibit 
both angiogenesis and lymphangiogenesis in cancer and to enhance anti-tumour 
immunity. 
 
Materials and Methods 
Cell culture  
HDLECs (#CC2812, Lonza) and HMBECs (#CC2813, Lonza) were cultured in 
endothelial basal medium (EBM)-2 media supplemented with endothelial growth medium 
(EGM)-2-MV Singlequots (Lonza) and 10 mM 4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES; Life Technologies). These cells were from a single donor 
and guaranteed free of pathogens and contaminants by the manufacturer. Tissue culture 
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treated plates were coated before use with 5 μg/ml human fibronectin solution (BD 
Bioscience). Cells were used at passage number 5. Primary human dermal fibroblasts 
isolated from foreskins, kindly provided by Dr. Pritinder Kaur (Peter MacCallum Cancer 
Centre), were grown in DMEM supplemented with 10% fetal calf serum (FCS; v/v), non-
essential amino acids, 10 mM HEPES and penicillin-streptomycin (Life Technologies).  
 
siRNA screen and scratch wound assay. 
Detailed Minimum Information About an RNAi Experiment (MIARE)-compliant 
screening procedures are outlined in Data File S1, and complete protocols are described 
elsewhere (20). The genome-wide siRNA screen is performed in 96 well plates in 
technical duplicate (Corning Costar). HDLECs (15000/well) are reverse transfected using 
DharmaFECT transfection reagent #1 (0.2 μl/well) with 40 nM siRNA (Human 
siGENOME SMARTpool library [2009 ed.], Dharmacon RNAi Technologies). siRNA 
pools targeting CDC42 and CDH5 were included as positive controls (fig. S1, D to F). At 
48 h post-transfection cells are loaded with Celltracker Green 5-chloromethylfluorescein 
diacetate (CMFDA) live cell stain (5 μM; Life Technologies) before a 96-pin wounding 
device with ‘FP’ pins (V&P Scientific) controlled using a workstation robot (Sciclone 
ALH 3000, Caliper Life Sciences) is used to create uniform scratches (approximately 3.8 
mm long × 0.38 mm wide) in the cell monolayer (fig. S2, A to F). Cells are washed, and 
medium replaced. An image of the initial scratch area (A0) is then obtained as described 
in High content, high throughput imaging, before incubating at 37°C for a further 24 h. 
This timepoint represents ~50% closure of the original wound area (fig. S1 E; fig. S3), 
and is selected to enable detection of both accelerated and inhibited wound closure. At 
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the assay endpoint, cells are fixed with 4% paraformaldehyde (PFA), then permeabilised 
and blocked in 0.2% Triton X-100/2% bovine serum albumin  (BSA) in phosphate-
buffered saline (PBS) and stained with phalloidin CF488 (20 nM, Biotium) and Hoechst 
33342 (2 µg/ml, Life Technologies). An image of the remaining scratch area (A24) is 
obtained. The area migrated over by the cells in each well is then calculated as Am = A0 – 
A24 (fig. S2, E to F). These values are normalised to the median of mock-transfected wells 
per plate and averaged across technical replicates. Robust z scores are then generated 
across all plates (utilizing the median and median absolute deviation; MAD). The “Low 
Cell Count” threshold is set at < 60% of the median density per field. 
A curated list of 500 candidates identified in the primary screen is then assayed in a 
secondary deconvolution screen, with SMARTpool siRNA duplexes assayed 
individually. The gene list comprises 350 “Impaired” (robust z score <−2.3) and 50 
“Accelerated” candidates (robust z score >2.67). In addition, 65 candidate genes (|robust 
z score| >2) are selected based on known protein–protein interactions with other 
candidate genes, as these could assist in generating and understanding signalling 
networks. A further 12 candidates (|robust z score| >2) are selected based on microarray 
data indicating higher differential expression in HDLECs compared to HMBECs (see 
Microarray comparison of HDLECs and HMBECs) as these may represent lymphatic-
specific migration genes. The list is then rounded to 500 candidates (401 “Impaired” and 
99 “Accelerated”) by including the candidates with the next highest robust z scores. 
Transfection follows the protocol of the primary screen, with final siRNA concentration 
of 25 nM. Thresholds based on mean ± 3 SD of mock-transfected wells are set at 60% 
and 130% of mock-transfected cell migration for “Impaired” and “Accelerated” binning 
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respectively. A gene candidate is deemed validated (here “highly-validated”) if two or 
more of the four siRNA duplexes reproduced the original phenotype seen in the primary 
screen. 
In the tertiary screen, siRNA SMARTpools targeting the 154 “highly-validated” genes 
identified from the secondary screen are transfected into HDLECs and HMBECs in 
parallel, following the protocol of the primary screen. The endpoint of the migration 
assay for HMBECs, at which control scratch wounds were ~50% closed, was 
experimentally defined as 16 h post-scratch (fig. S6B). The screen is performed in 
biological duplicate for each cell type, with technical duplicate plates. At the endpoint, 
cells are additionally stained with Phalloidin CF555 (Biotium).  
Official Entrez Gene IDs and gene symbols are from the Human Genome Organisation 
(HUGO) Gene Nomenclature Committee website (www.genenames.org). Custom python 
or R scripts are used to quality control, analyse and decipher the siRNA datasets.  
 
High content, high throughput imaging 
Imaging and image processing is performed as described previously (20). Image fields 
are captured using a high-throughput imaging system (Pathway 435, BD Bioscience), 
stitched together on capture using acquisition software (Attovision v1.6.1, Becton 
Dickinson), then smoothed and flattened using image analysis software (MetaMorph 
v7.7.5.0 (64-bit), Molecular Devices). A fluorescence intensity threshold based on the 
CellTracker Green and phalloidin CF488 signal is then used to create a binary mask, 
which enables measurement of the wound area devoid of cells (Fig. S2 E to F). 
For counting of cell nuclei, a high-content imaging platform (Cellomics VTI Arrayscan, 
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Thermo Fisher Scientific) is used to acquire 30 adjacent fields per well of cells stained 
with Hoechst 33342. Thresholding of images is used to identify and count the number of 
cell nuclei per field.  
For cell morphology analysis, cells are additionally stained with Phalloidin CF555 to 
discriminate filamentous actin. Images are segmented into nuclei and cell body areas 
using MetaMorph. Segmented areas are then subjected to measurement of various 
parameters describing cell size and shape, and actin staining intensity as enabled by the 
Integrated Morphometric Analysis module in MetaMorph (see parameters listed in Fig. 
3B). Data for each parameter are normalized into z-scores, and the combined dataset of 
morphological parameters is then used to determine “clusters” of siRNA target genes 
whose knockdown generated similar morphologies, as described (20). Briefly, the 
normalized morphology dataset is subjected to unsupervised hierarchical clustering in 
CIMminer (http://discover.nci.nih.gov.cimminer/) using Complete linkage cluster 
method, Correlation distance algorithm and Quantile binning settings. The resulting 
dendrogram of relatedness (correlation) between genes according to their corresponding 
morphology parameters is divided into six clusters, guided by a 1-Pearson correlation 
cutoff of 1.5. 
 
Antibodies 
Antibodies used for immunofluorescence microscopy and Western Blotting were rabbit 
polyclonal antibodies against human LYVE1 (Fitzgerald RDI), PROX1 (Covance), 
CEACAM-1 (Abcam) and vWF (DAKO); mouse monoclonal antibodies against human 
VEGFR3 (clone #54703; R&D Systems), α-smooth muscle actin (α-SMA; clone #1A4, 
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Sigma), CD146 (clone #P1H12 or SHM-57; BioLegend), CD31 (clone #MEC13.3) 
PNAd (clone #MECA-79, BD Pharmingen)  and CDH5 (VE-cadherin; clone #55-7H1, 
BD Pharmingen). Rabbit polyclonal antibodies to human Podoplanin (Fitzgerald RDI) 
and mouse monoclonal antibodies to human CDH2 (clone #5C8, Sigma-Aldrich) and 
PLVAP (clone #174/2, Hycult Biotech) were used for flow cytometry. A goat polyclonal 
antibody recognising human Galectin-1 (R&D Systems) and mouse monoclonal antibody 
to Podoplanin (clone #D2-40; Genway) were used for immunohistochemistry. For 
Western Blotting, rabbit antibodies against phosphorylated VEGFR2 (Tyr1175, clone 
#19A10), total VEGFR2 (clone #55B11), phosphorylated ERK1/2 (Thr202/Tyr204), total 
ERK2, phosphorylated AKT (Ser473, clone #D9E), phosphorylated Src family kinases 
(Tyr416, clone #D49G4) and CDC42 (clone #11A11), as well as mouse antibodies to total 
Akt (clone #40D4) and total Src family kinases (clone #L4A1) were all obtained from 
Cell Signaling Technology. A mouse monoclonal antibody to human α-tubulin (clone 
#DM1A; Abcam) or rabbit antibodies to human GAPDH (clone #14C10, Cell Signaling 
Technology or FL-335, Santa Cruz) were used for loading controls. Isotype control 
antibodies used for various experiments were mouse IgG1 (BioLegend), rabbit IgG 
(Imgenex) and goat IgG (Genetex). For immunofluorescence and flow cytometry, goat 
antibodies recognizing rabbit or mouse IgG and conjugated to Alexa Fluor 488 or 546 
were used. For Western blotting, secondary antibodies recognising goat, mouse or rabbit 
IgG conjugated to IRdye 800 or IRdye 680 (LI-COR) were used.  
 
Signaling pathway analysis 
Pathway analysis software (Metacore, GeneGo, Thompson Reuters) was used to search 
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for signaling pathways (“Pathway Maps”) and cellular processes (“GO Processes”) that 
were overrepresented in the datasets. Input datasets are compared to lists of genes within 
the database that are annotated to particular terms (such as a given “Pathway Map”). P 
values calculated in enrichment analyses indicate the probability that the number of genes 
represented in both the input dataset and the annotated term list is random, and are 
derived according to hypergeometric distributions.  
The software also allowed construction of protein–protein interaction networks using 
various algorithms as follows. A “direct interactions” or a “shortest paths” algorithm 
(maximum number of steps = 2, not canonical pathways) was used for generating 
signaling networks (Fig. 5). Networks were constructed to identify protein-protein 
interactions using direct interaction types (such as phosphorylation, binding, cleavage), 
however, indirect interactions (“transcriptional regulation” and “influence on 
expression”) were excluded. Open-source software (Cytoscape v.2.8.2; 
www.cytoscape.org) was employed for visualizing and integrating data into networks, 
following data importation from Metacore using the plugin 
“com.genego.cytplugin.NetworkLoader” (v.0.1). Construction of an ontology tree was 
performed using GOrilla (http://cbl-gorilla.cs.technion.ac.il/), which enabled comparison 
of the candidate gene list with the rest of the human genome. 
 
Isolation of LN stromal and endothelial cells in a cutaneous HSV-1 infection model. 
All animal experiments were conducted under the approval of the Animal Experimental 
Ethics Committees at Peter MacCallum Cancer Centre or the Peter Doherty Institute. 
Detailed protocols for LN stromal cell subset isolation and microarray analysis (see 
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below) are described elsewhere (45, 91). Briefly, C57Bl/6 mice are inoculated with HSV-
1 onto a patch of abraded skin. Brachial LNs draining the infection site are harvested 
from uninfected mice or on day 6 after inoculation and digested to a single-cell 
suspension for flow cytometric cell sorting. After gating out residual CD45+ leukocytes, 
LECs are defined as Podoplanin+CD31+, BECs as Podoplanin-CD31+, and FRCs as 
PodoplaninlowCD31-.  
 
Microarray analysis of LN stromal cell subsets and list overlap analysis. 
Biotinylated cDNA derived from sorted LN cell subsets is hybridized to GeneChip 
MouseGene 1.0 ST chips (Affymetrix).  After processing and normalization of 
microarray probe intensity data using robust multi-array analysis (RMA) (92), differential 
expression is analyzed using the limma software package (93) in BioConductor (94). 
TREAT (T-tests RElative to A Threshold) empirical Bayes t-tests (95) relative to a fold 
change threshold of 1.1 are applied to determine significance of differential expression, 
with the false discovery rate (FDR) set at 5%. This dataset is published (45) and 
deposited in the Gene Expression Omnibus (GEO) database (www.ncbi.nlm.nih.gov/geo; 
GSE84284). The same analysis was also applied to a publicly-available microarray 
dataset comprising LECs isolated from untreated and CHS-inflamed mouse ears (46). 
The matrix file containing RMA-normalised data from the GeneChip Mouse Genome 430 
2.0 Array (Affymetrix) was downloaded from GEO (accession number GSE26229), and 
differential expression analysed using limma with TREAT criteria as above. In the case 
of multiple probes per gene, a single representative probe was chosen. 
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For the comparison between the microarray datasets and siRNA screen results, we 
applied a further threshold of |linear fold-change| ≥1.8 on top of the 5% false discovery 
rate (FDR; P  < 0.05 after adjustment for multiple testing) to increase stringency on the 
biological significance of changes in mRNA expression. For the LN stromal cell dataset, 
lists of genes that were selectively differentially-expressed by the three cell types (BEC, 
LEC or FRC) were also derived as described in Fig. 6D to interrogate shared and cell 
type-selective effects. Differentially-expressed genes were considered to be “-selective” 
to the designated cell type or types in this experimental context if they were either not 
differentially expressed (i.e. |fold-change|<1.8), or discordantly differentially expressed 
(i.e. |fold-change|≥1.8 in the opposite direction) in the other cell types. For the CHS 
dataset (46), only one cell type had been analysed so all genes differentially-expressed 
with |linear fold change| ≥ 1.8 and adjusted P > 0.05 were included, analogous to the LEC 
total list from the LN stromal cell dataset (Fig. 6D). Mouse gene symbols from 
microarray data were converted to human orthologs using the HUGO Gene Nomenclature 
Committee Comparison of Orthology Predictions (HCOP) retrieved from 
http://www.genenames.org/cgi-bin/hcop, selecting the ortholog predicted by the greatest 
number of databases. Sorted lists of differentially-expressed genes from the microarray 
datasets were then compared with genes identified from the siRNA screen experiments to 
derive lists of overlapping genes. Data presented are derived from pooled lists of all 
increased and decreased differentially-expressed genes fitting the above criteria compared 
to “Accelerated” and “Impaired” “expanded migration candidates” with |robust z score| 
≥1.6449 in the primary siRNA screen, representing the top 5% and bottom 5% of scores. 
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Genes binned as “Low Cell Count” in the primary screen were excluded prior to overlap 
analysis.  
Statistical significance of overlap was determined empirically using simulated null 
distributions, a useful strategy for comparing similarity of gene lists from different 
sources (96). These were derived by determining the overlap between 10,000 pairs of 
random gene lists of the same size as derived by the criteria above, relative to the 
complete list for each different analysis platform (18,120 human genes for the Human 
siGENOME SMARTpool library; 21,041 mouse genes for the GeneChip MouseGene 1.0 
ST microarray; 21,723 genes for the GeneChip Mouse Genome 430 2.0 Array). Genes 
were indexed as integers and randomly sampled without replacement, assuming that the 
mouse microarray probes have one-to-one mapping to human siRNA targets and that the 
genes covered by the microarray are a superset of the genes targeted in the siRNA library. 
The size of the lists of overlapping genes was then assessed for significance against the 
null distribution. Analyses were performed using R statistical software. As a further 
validation, significance was also computed based on hypergeometric distribution over the 
common set of genes between the two platforms. Hypergeometric P values correlated 
with empirical P values calculated from simulated null distributions, and gave a more 
conservative estimate of significance.  
 
Tube formation and co-culture assays 
HDLECs were reverse transfected with gene-targeting siRNA SMARTpools or a control 
siRNA (ON-TARGETplus Non-targeting control pool, Dharmacon). For short-term 
overlay tube formation assays, 48 h post-transfection the cells were overlaid with 100 μl 
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neutralized collagen solution (Bovine Type 1, Gibco) and incubated at 37°C, 5% CO2 for 
8 h to allow tube formation to occur (97). Collagen overlaid cells were fixed in 4% PFA 
and permeabilized with 0.2% Triton-X 100, 1% BSA in PBS. Cells were washed with 
PBS and stained with phalloidin CF488 (20 nM, Biotium) and Hoechst 33342. Images 
were captured (Cellomics VTI Arrayscan, Thermo Fisher Scientific) using a 5× Fluar 
NA0.25 objective (Carl Zeiss), with 9 adjacent fields imaged per well. Images were auto-
contrast adjusted using Adobe Photoshop CS4 (Adobe Systems Incorporated), and 
quantified using a custom analysis protocol established in image analysis software 
(MetaMorph). The co-culture assays were performed as described previously (98) with 
the following modifications. Briefly, 104 primary dermal fibroblasts per well were grown 
in 96 well plates. 24 h after siRNA treatment, HDLECs were seeded at 1.5x103 cells per 
well onto the fibroblast feeder layer and grown for nine days before fixation and 
processing for immunofluorescence microscopy. Tubule formation was analysed using 
either ImageJ or Angioquant (http://www.cs.tut.fi/sgn/csb/angioquant/) programs. 
 
SDS-PAGE and Western blotting 
Protein abundance was assessed using SDS-PAGE and Western blotting as described 
previously (99). Briefly, for analysis of phosphorylation in VEGFA and VEGFC 
signaling pathways, siRNA-treated cells were serum-starved in MCDB-131 media (GE, 
Life Technologies) supplemented with 0.2% BSA for 2-4 h prior to stimulation with 
recombinant human VEGFA165 (R&D Systems) or mature VEGFC (Opthea) for indicated 
times. Cells were washed 3 times in ice-cold PBS prior to lysis in 2% sodium dodecyl 
sulfate (SDS) Buffer (2% SDS, 50mM Tris, 150mM NaCl, 2mM 
ethylenediaminetetraacetic acid [EDTA], 2mM  ethylene glycol-bis(β-aminoethyl ether)-
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N,N,N',N'-tetraacetic acid [EGTA], 1mM phenylmethylsulfonylfluoride) and protein 
quantification by bicinchoninic acid assay (Pierce). 10-15 µg total protein was separated 
on 4-20% Bolt gels before transfer using the iBlot system (GE, Life Technologies). 
Western blotting was performed using primary antibodies as described above and imaged 
using either Odyssey CLx Imaging System (LI-COR) for infrared fluorescence detection 
or a GelDoc (BioRad) for chemiluminescence-based development. 
 
Injection of Matrigel Plugs into Mouse Ears   
Recombinant mouse Gal-1, VEGFA, a mature form of mouse VEGFD, Anginex or BSA 
(Control) were resuspended in 30 μl of Matrigel (Matrigel Basement Membrane Matrix, 
BD Biosciences) at either 10 or 25 µg/ml final concentration and injected into the center 
of 6-8-week old female SCID/NOD (severe combined immunodeficent/nonobese 
diabetic)/Gamma mouse ears. At 5 days post injection, ears were harvested, fixed and 
processed for staining of lymphatic (LYVE-1 or Podoplanin) and blood vasculature 
(CD146 or αSMA). Images were captured on either Pathway 435 or BX61 (Olympus) 
microscope and analyzed using Metamorph and AngioTool software.  
 
Immunofluorescence staining and quantitation 
Cells were treated as for the siRNA screen and scratch wound assay and subsequently 
stained with appropriate primary and fluorescently-conjugated secondary antibodies. 
Fluorescence images were captured using the Cellomics VTI Arrayscan or Pathway 435 
automated high-throughput microscopy platforms. To quantify immunofluorescence 
staining for particular antigens, fluorescence intensity was measured using ImageJ 
following the application of a common threshold across all samples within a single 96-
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well plate. A mask was applied based on the highest-expressing sample and pixel 
intensity determined across the various conditions. Immunofluorescence staining of 
mouse LN sections is described elsewhere (45). 
 
Immunohistochemistry 
Human lymph node tissue sections were obtained from the Molecular Pathology 
Department, Peter MacCallum Cancer Centre. Samples were from breast cancer patients 
with no lymph node metastases. Samples were obtained with informed consent, and used 
under appropriate institutional approval. Microwave antigen retrieval of paraffin 
embedded sections was performed using target retrieval solution (DAKO), for 15 min on 
medium low setting. Endogenous peroxidase was blocked by washing slides in 3% 
H202/methanol for 20 min, and then adding serum-free blocking solution (DAKO) for 1 h. 
Sections were immunostained with a goat antibody recognizing human Gal-1 (1:100), or 
a mouse antibody against Podoplanin (1:100), and an appropriate biotinylated secondary 
antibody. Signal was amplified using Vectastain ABC (Vector Laboratories), and 
developed using liquid diaminobenzidine (DAB) (Peroxidase Substrate Kit, Vector 
Laboratories). Slides were subsequently visualized and imaged using a microscope 
(BX61, Olympus) with 60× UPlanSApo NA1.20 objective (Olympus) and digital camera 
(SPOT RT3 Slider, Diagnostic Instruments). 
 
qRT-PCR 
Total RNA isolated from HDLECs was reverse-transcribed using the High-Capacity 
cDNA reverse transcription kit (Applied Biosystems) according to the manufacturer’s 
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instructions. Expression of selected genes was then assessed using Taqman gene 
expression assays and gene expression master mix (Applied Biosystems). Target 
abundance was normalized to GAPDH. 
 
Oncomine™ data analysis 
The relative expression of individual candidate migration genes in human breast tumor 
stroma samples was determined by searching the Oncomine database (version 4.4.3, 
September 2012 data release, www.oncomine.org). Target genes (for example LGALS1) 
were queried, and output data was sorted to isolate “cancer versus normal” associations, 
filtered using the tissue subtype “stroma”. Data is reported as the log2 median-centered 
expression values for normal breast and breast carcinoma samples using box-and-
whiskers plots. LGALS1 expression in normal compared to cancer groups was compared 
within Oncomine using a two sample t-test. 
 
Thoracic Duct and Aortic ring sprouting assay 
Thoracic ducts and aortae from male or female 6-12 week-old C57Bl/6 mice were 
isolated and processed for the assay essentially as outlined by Bruyère et al. (91) or Baker 
et al. (92) with some modifications. Briefly, small sections of upper thoracic duct or aorta 
were micro-dissected and embedded in neutralized type I rat tail collagen (1 mg/ml in 
Opti-MEM [Life Technologies] supplemented with 2% FCS). Explants were grown for 5 
days in Opti-MEM supplemented with 10% FCS for thoracic ducts or 2.5% FCS for 
aortae and either growth factors, recombinant Gal-1 or Anginex. Collagen gels were fixed 
in 4% PFA, permeabilised with 0.25% Triton-X-100 in PBS, and stained for sprouting 
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endothelium (Bandiera (Griffonia) Simplicifolia (BS)1-Lectin-FITC) and outgrowing 
supporting cells (Phalloidin-Alexa Fluor 555). Images were captured on a Pathway 435 
and collapsed z-stack images were quantified using ImageJ for endothelial outgrowth 
area and tubule length. Sprout numbers were manually scored.     
 
Microarray comparison of HDLECs and HMBECs 
Publicly available microarray dataset GSE6550-GPL570 was accessed through GEO. The 
GEO2R analysis function on the website was used to analyze the data and calculate the 
fold change in expression for each gene between blood and lymphatic ECs. The values of 
multiple probes were averaged, and a mean fold-change of ≥ 10 was used to select genes 
with differential expression. 
 
General statistical analysis 
For experiments involving comparison of treated and control groups, a two-tailed 
Student’s t-test was used. A one-way analysis of variance (ANOVA) test with Dunnett 
(comparison to control) or Tukey (comparison to all samples) post-hoc test was used for 
comparison of multiple groups in various experiments. With the exception of the list 
overlap analyses, and analyses performed within Metacore and Oncomine, statistical 
analyses were conducted using Graphpad Prism software (versions 5-7). P < 0.05 was 
considered statistically significant. The appropriateness of the tests used has been 
affirmed by Dr. E. Link, a senior statistician at Peter MacCallum Cancer Centre. 
 
Supplementary Materials 
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Figure Legends 
Fig. 1. Overview of lymphatic endothelial cell migration screen and analyses 
(A) HDLEC monolayers were transfected with CDC42 or CDH5 siRNA pools (as 
positive controls) and subjected to the scratch wounding assay. Values represent the 
percentage migration relative to the mean of mock-transfected (Control) cells. Scale bar, 
500 μm. (B) Plot of the primary screen results for each siRNA pool. Migration scores 
plotted on the x-axis are expressed as robust z scores. Each point represents the average 
of two replicate wells per gene-specific siRNA pool. Results with |robust z score| > 2 
(dashed vertical lines) were considered as “Accelerated” or “Impaired” “migration 
candidates”, and those with cell density <60% of the median per field (dashed horizontal 
line) were classified as “Low Cell Count”. (C) Schematic representation of the 
relationships between datasets, experimentally-derived gene lists and specific analyses 
within this study. Blue boxes, complete datasets. Red boxes, summaries of the siRNA 
migration screens. Other boxes, specific analyses. Bullet points, the gene list input into 
the given analysis or Data File. The gene list size and the Data File containing the results 
are indicated. MIARE, Minimum Information About an RNAi Experiment.  
 
Fig. 2. Functional categorization of highly-validated genes that promote lymphatic 
endothelial cell migration 
Annotation of the 154 “highly-validated” candidates into groups reflecting their 
functional role in the cell, based on literature and text-mining and Metacore analysis (fig. 
S4, and Data Files S5, S6). Connecting lines represent protein–protein interactions.  
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Fig. 3. Morphological changes induced by siRNAs targeting validated candidate genes 
(A) Fluorescent microscopy images of cells stained with Celltracker Green (whole-cell) 
and Phalloidin CF555 (filamentous actin) were subjected to automated high content 
analysis of cellular regions. Green lines delineate valid cell segmentation boundaries. 
Scale bar, 250 μm. (B) Unsupervised clustering of candidate genes and cell 
morphological parameters (such as size, shape, actin intensity) allows identification of 
genes that regulate similar aspects of cell morphology. Selected example candidates are 
indicated below the heatmap. (C) Examples of morphological changes observed 
following transfection with siRNA pools in cluster 2 (see also fig. S5). Scale bar, 250 μm. 
(D) Comparison of four distinguishing morphological parameters across morphology 
clusters. A schematic diagram of representative morphology, with actin in orange, is 
depicted for each cluster. 
 
Fig. 4. Evaluation of highly-validated candidate migration genes in HMBECs 
Migration was assessed in HMBECs and HDLECs transfected with siRNA pools 
targeting the 154 “highly-validated” candidate genes. (A) Dotplot comparing the 
migration screen results in HDLECs (x-axis) compared to HMBECs (y-axis). Each 
datapoint represents a gene-specific siRNA pool, represented as the average migration 
score of two biological replicates (each comprising technical duplicate wells), relative to 
mock-transfected controls. Results with migration scores below 0.65 (dotted lines) in 
HDLECs and/or HMBECs were classified into the indicated categories (quadrants). (B) 
Migration phenotypes resulting from transfection of HMBECs or HDLECs with the 
indicated siRNA pools. Cells are labelled with Celltracker Green. Scale bar, 500 μm. (C) 
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Lists of the genes identified as having LEC-dominant and BEC-dominant effects on 
migration. Inset numbers represent the morphology clusters as defined in Fig. 3. (D) 
Heatmap of HMBEC morphology parameters. Gene and parameter order was not 
subjected to hierarchical clustering, but was kept the same as in Fig. 3B to highlight the 
similarities and differences in morphological phenotypes observed between the two cell 
types. Selected example candidates are labelled below the heatmap. (E) Comparison of 
the morphological changes that are induced by transfection of HMBECs and HDLECs 
with an siRNA pool targeting LPL (see also fig. S7C).  Scale bar, 250 μm. 
 
Fig. 5. The endothelial cell migratome 
The 68 Common EC migration candidates and 20 LEC Dominant candidates were 
analysed for protein-protein interactions, identifying two-step pathways between many 
validated EC migration genes. Migration candidates are colour-coded to match Fig. 4, A 
and C. Coloured boxes with dashed outlines indicate functional categories.   
 
Fig. 6. Overlap between migration candidate genes and genes differentially-expressed 
during lymphatic remodeling in vivo 
(A) Immunofluorescence staining of LNs from uninfected control mice (Day 0) and 5 
days after subcutaneous HSV-1 infection (Day 5), to identify lymphatic vessels (LYVE-
1), high endothelial venules (PNAd) and all other endothelium (CD31). Scale bar, 200 
µm. (B) The list of genes differentially expressed (HSV-1 day 6 compared to day 0) in 
LN LECs in the microarray analysis was compared to the “expanded migration 
candidate” list from the primary siRNA screen (excluding “Low Cell Count” genes) to 
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determine the number and significance of overlapping genes. Significance of overlap was 
defined against a simulated null distribution derived from 10,000 random pairs of gene 
lists of equivalent size as described in Materials and Methods. (C) Venn diagram of the 
number of input and overlapping genes from the analysis in (B). ***Empirical P value < 
0.001; hypergeometric P value = 0.0078 (D) Filtering of differentially-expressed genes 
into cell-selective and shared categories, and comparison of these gene lists to the 
“expanded migration candidate” list. Empirical P values were determined according to 
simulated null distributions as in (B); hypergeometric P values are in footnote b. (E) 
Venn diagram of the number of overlapping genes identified between the different 
categories of differentially-expressed genes in (D) with genes identified in the primary 
siRNA screen. Intersections are exclusive of one another and colour-coded to match (D). 
*P < 0.05, **P < 0.01 empirical P values. (F) Venn diagram of overlapping genes 
between those differentially-expressed in dermal LECs during CHS (24 h compared to 
unstimulated) and the “expanded migration candidate” list. *P < 0.05 empirical P value; 
hypergeometric P value = 0.0547. 
 
Fig. 7. Galectin-1 regulates lymphatic endothelial cell migration in vitro and in vivo 
(A and B) Western blotting for Gal-1 in cultured HDLECs and HMBECs (A), and in 
HDLECs transfected with LGALS1 siRNA pool (B). “Control” indicates mock-
transfected cells in (B) and (D-G); non-targeting siRNA in (C). (C) Quantitation of Gal-1 
knockdown by Western blotting. Mean ± SEM of n = 4 independent experiments; ****P 
< 0.0001 by Student’s t test. (D) Tube network formation under Collagen I gel by 
HDLECs. Scale bar, 250 μm. Mean ± SEM of three independent experiments shown; *P 
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< 0.05 by Student’s t test. (E) HDLECs with or without LGALS1 knockdown were grown 
on a confluent fibroblast monolayer before CD31 and LYVE1immunofluorescence was 
performed to visualise HDLECs and smooth muscle actin (SMActin) to stain fibroblasts. 
Scale bar, 250 μm. (F, G) Tubule networks from (E) were quantified by the parameters 
indicated. Mean ± SEM of three independent experiments; (F) *P < 0.05 by ANOVA 
with Tukey post-hoc test; (G) P = 0.05 by Student’s t test. (H) Immunofluorescence for 
LYVE-1 (lymphatics), and CD146 (blood vessels) on mouse ears injected with the 
indicated proteins in Matrigel, with or without the Gal-1 inhibitor Anginex. Scale bar, 
250 μm. Lymphatic vessel width and density was quantitated. n = 9 mice with 9-18 ears 
per condition across two independent experiments. Mean ± SEM; *P < 0.05, **P < 0.01 
by ANOVA with Tukey post-hoc test. (I) Immunohistochemistry on serial sections of 
human LN. White arrows: lymphatic vessel (LV). Black arrowhead: blood vessel (BV). 
Scale bar, 50 μm. (J) Bioinformatic interrogation of two published gene expression 
datasets (100, 101) for LGALS1 expression in normal tissues and cancer stroma. Central 
line, median; box, interquartile range; whiskers, 90/10 percentiles; dots, 
minimum/maximum; P values determined in Oncomine using two-sample t test. 
 
Fig. 8. Gal-1 signalling maintains lymphatic endothelial cell phenotype 
(A) HDLECs transfected with LGALS1 siRNA pools were serum-starved before 
stimulation with VEGFA (20 ng/ml) then analysed by immunoblotting. Control, non-
targeting siRNA; Src, Src family kinases. (B) Quantification of phospho (p)-VEGFR2, p-
ERK 1/2 and p-Akt bands in (A), normalised to the total respective protein and expressed 
relative to unstimulated Control-transfected cells. Mean ± SEM; n = 3-6 independent 
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experiments; *P < 0.05, **P < 0.01 by ANOVA with Tukey post-hoc test. (C) 
Quantification of total VEGFR3 bands in (A) normalised to loading control; mean ± SEM 
shown; n = 3 independent experiments; *P < 0.05 by Student’s t test. (D) 24 h following 
scratch-wounding, siRNA-treated HDLECs were examined by immunofluorescence for 
indicated proteins; nuclei were counterstained with Hoechst 33342 (Hoechst). Scale bar, 
250 µm. For quantification see fig. S12A. (E,F) Lysates of HDLECs transfected as 
indicated were analysed after 72 h by Western blotting for LEC, BEC or common 
endothelial lineage marker proteins. (G) Quantitation of Western blot analyses of 
respective LEC and BEC marker proteins in (E,F), normalised to loading control. Mean ± 
SEM; VEGFR2 n = 8 independent experiments; VEGFR3 n = 10 independent 
experiments; CD146 n = 6 independent experiments; CEACAM1 n = 5 independent 
experiments; Podoplanin n = 3 independent experiments; Prox1 n = 5 independent 
experiments. *P < 0.05, **P < 0.01 by ANOVA with Dunnett post-hoc test.  
 
